Health News

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Pharmacy

Related posts

• Zoledronic acid may extend survival in older breast cancer patients (0)
  A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds. Read more [tags] Pharmacy News [/tags]
  
  
• Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal breast cancer (0)
  The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer (0)
  ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• ZEN bust-enhancing supplements may increase risk of breast cancer (0)
  Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of [...]
  
  
• YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR (0)
  YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly [...]